tradingkey.logo

Bluejay Diagnostics Inc

BJDX

1.490USD

-0.010-0.67%
Horarios del mercado ETCotizaciones retrasadas 15 min
825.48KCap. mercado
PérdidaP/E TTM

Bluejay Diagnostics Inc

1.490

-0.010-0.67%
Más Datos de Bluejay Diagnostics Inc Compañía
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
Información de la empresa
Símbolo de cotizaciónBJDX
Nombre de la empresaBluejay Diagnostics Inc
Fecha de salida a bolsaNov 10, 2021
Director ejecutivoMr. Neil (Indranil) Dey
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 10
Dirección360 Massachusetts Avenue, Suite 203
CiudadACTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01720
Teléfono19786310152
Sitio Webhttps://bluejaydx.com/
Símbolo de cotizaciónBJDX
Fecha de salida a bolsaNov 10, 2021
Director ejecutivoMr. Neil (Indranil) Dey
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
Desglose de ingresos
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Armistice Capital LLC
0.47%
L1 Capital Global Opportunities Master Fund Ltd.
0.18%
Tower Research Capital LLC
0.12%
UBS Financial Services, Inc.
0.05%
Lana Management & Business Research International LLC
0.03%
Other
99.15%
Accionistas
Accionistas
Proporción
Armistice Capital LLC
0.47%
L1 Capital Global Opportunities Master Fund Ltd.
0.18%
Tower Research Capital LLC
0.12%
UBS Financial Services, Inc.
0.05%
Lana Management & Business Research International LLC
0.03%
Other
99.15%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
0.58%
Corporation
0.21%
Investment Advisor
0.05%
Individual Investor
0.04%
Other
99.11%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
29
13.35K
0.89%
-11.19K
2025Q1
33
13.32K
1.15%
-11.19K
2024Q4
33
13.25K
2.40%
-10.14K
2024Q3
34
31.07K
8.08%
+26.51K
2024Q2
34
7.19K
9.21%
+4.96K
2024Q1
32
2.22K
59.41%
+553.00
2023Q4
32
1.63K
54.54%
+399.00
2023Q3
33
1.19K
46.18%
+12.00
2023Q2
32
1.16K
61.50%
-18.00
2023Q1
29
1.15K
45.43%
-4.00
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
L1 Capital Global Opportunities Master Fund Ltd.
2.68K
0.18%
+2.68K
--
Jun 27, 2024
Tower Research Capital LLC
1.74K
0.12%
+1.19K
+213.90%
Mar 31, 2025
UBS Financial Services, Inc.
812.00
0.05%
-1.13K
-58.25%
Mar 31, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
Dey (Indranil)
90.00
0.01%
--
--
May 02, 2025
SBI Securities Co., Ltd.
20.00
0%
+20.00
--
Mar 31, 2025
Cook (Jason John)
13.00
0%
--
--
May 02, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Fecha
Tipo
Relación
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Nov 13, 2024
Merger
50<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jun 17, 2024
Merger
8<1
Jul 21, 2023
Merger
20<1
Jul 21, 2023
Merger
20<1
Ver más
KeyAI